Skip to main navigation
Skip to search
Skip to main content
Sort by
Medicine and Dentistry
Hepatocellular Carcinoma
100%
Tumor Microenvironment
54%
Atezolizumab
42%
Bevacizumab
42%
Cytotoxic T-Cell
25%
Computer Assisted Tomography
22%
Cancer Cell
21%
Systemic Therapy
20%
Mitochondrion
20%
Malignant Neoplasm
19%
Neoplasm
19%
Hepatic Portal Vein
17%
Lenvatinib
16%
Ion Therapy
14%
Tumor Thrombus
14%
Vascular Tissue Neoplasm
14%
T-Helper Cell
13%
Liver Biopsy
12%
Microsatellite Instability
12%
Puncture
12%
Immunosuppressive Treatment
12%
Ramucirumab
12%
Biopsy Technique
12%
Pulmonary Hypertension
12%
Portal Hypertension
12%
Cancer Therapy
12%
Particle Therapy
12%
Ticilimumab
12%
Durvalumab
12%
Disease
12%
Immune Evasion
12%
Immunocompetent Cell
12%
Tumor Progression
11%
Tumor Biopsy
10%
Vessel Diameter
10%
Adverse Event
9%
Embolization
9%
Absorbable Gelatin Sponge
9%
Diagnosis
9%
Gelatin
9%
Liver Tumor
9%
Progression Free Survival
8%
Esophageal Varices
7%
Tumor Immunity
6%
Immune Checkpoint Inhibitor
6%
Portosystemic Anastomosis
5%
Hepatic Encephalopathy
5%
Ammonium
5%
Fibroblast
5%
Keyphrases
Hepatocellular Carcinoma
33%
Atezolizumab Plus Bevacizumab
30%
Advanced Hepatocellular Carcinoma
25%
Systemic Therapy
18%
Portal Vein Tumor Thrombus
17%
Tumor Microenvironment
16%
Lenvatinib
16%
Hepatocellular Carcinoma Patients
13%
Portal Hypertension
12%
Associated Complications
12%
Ramucirumab
12%
CTNNB1
12%
Clinical Risk Factors
12%
Liver Tumor Biopsy
12%
Treatment Line
12%
Intracranial Progression
12%
Miglustat
12%
Glucosylceramide Synthase Inhibitor
12%
Real-world Practice
12%
Carbon Ion Radiotherapy
12%
Pulmonary Arterial Hypertension
12%
CTNNB1 mutation
12%
Computed Tomography
12%
Portal Vein Invasion
12%
Early Clinical Exposure
12%
Antigenicity
12%
Regulatory T (Treg) Cells
12%
Programmed Death-ligand 1 (PD-L1)
12%
Follicular Helper Cells
12%
Far Left
12%
Cell-Associated
12%
Tumor Immunity
12%
Imperial Strategy
12%
Cancer Cells
12%
Source Data
12%
Minor Change
12%
Immune Evasion
12%
Transcription Error
12%
Mitochondrial Transfer
12%
Cancer-associated Fibroblasts
12%
Spatial Interaction
12%
Calculation Error
12%
Cancer Stromal Cell
12%
Contrast-enhanced Computed Tomography
10%
Vessel Diameter
10%
Atezolizumab
8%
Bevacizumab
8%
Spatial Relationship
7%
Mixed Distribution
7%
Three-dimensional Construction
7%
Immunology and Microbiology
Cancer Cell
53%
Mitochondrion
38%
Bevacizumab
37%
Immune Evasion
37%
Atezolizumab
37%
T Cell
25%
Regulatory T Cell
25%
Immunosuppression
17%
Tumor-Infiltrating Lymphocytes
16%
Cytotoxic T-Cell
15%
Cancer Associated Fibroblast
15%
T-Helper Cell
13%
Antigenicity
12%
Natural Killer Cell
12%
Cytotoxic T Cell
12%
Computer Assisted Tomography
12%
Somatic Mutation
12%
Gene Function
12%
Neoantigen
12%
Immunocompetent Cell
12%
Tumor Cell
12%
Immunosuppressive Drug
10%
Wild Type
10%
DNA Mutation
10%
Cytotoxicity
9%
Tumor Immunity
7%
Cell Infiltration
7%
Fibroblast
7%
Mitophagy
7%
Carcinoma Cell
7%
Programmed Cell Death 1
6%
Gene Mutation
6%
MHC Class I
6%
Monoclonal Antibody
5%
Vasculotropin
5%
Overall Survival
5%
Cancer Immunotherapy
5%